Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of two dosing regimens
of FG-3019 administered over 12 weeks in patients with diabetic nephropathy and proteinuria
on background angiotensin converting enzyme inhibitor (ACEi) and/or angiotensin II receptor
antagonist (ARB) therapy.